definiens: means the confidential disclosure agreement entered into between the Parties dat ed 6 January 2017 ; means a period of three ( 3 ) consecutive months endi ng on the last day of March, June, September and December, respectivel y ; shall have the meaning set out in Clause 8.2 ; means, with respect to a Party, those efforts to be made by that Party corresponding to the efforts that Party would make in similar circumstances for its own similar products, and if it has no such similar products, those efforts that would be made by its n earest competitor, at that time relative to the prevailing commercial, re gulatory and competitive environment, which efforts shall be con sistent with the exercise of prudent scientific and business judgmen t, it being understood that a Party ’s Commercially Reasonable E fforts will not in any event require that Party to take any action tha t would be reasonably likely to result in a breach of any provision of th is Agreement, or any other agreement between the Parties, or a conflict with, or violation or default of, any other agreement between a Party, Af filiate of such Party and/or Third Parties existing as of the Effective D ate, or which that Party in good faith believes may violate any Applic able Laws or any instrument, judgment, writ, decree, order, permit, direction or licence of any court or Regulatory Authority having appropr iate jurisdiction over that Party ; means the pre - agreed criteria between the Parties w hich, once met, evidences that the Feasibility Study has been succe ssful, as detailed in Schedule 4 ; means an inhaler device to be determined by [COMPANY] ; means a detailed written description of agreed acti vities to be performed by [COMPANY] ( and/or an Affiliate of Vectur a and/or a Sub - Licensee ) and [COMPANY] to advance the development, regulatory compliance, Manufacturing and commercialisation of the Product ; means the novel proprietary kinase inhibitors acqui red by [COMPANY] from Respivert Limited as announced by [COMPANY] on 13 June 2017, known by [COMPANY] at the Effective Date as PUR1800, PUR5700 and RV568, as more specifically described in Schedule 6 ; means a certain study with a view to developing the Study Product in accordance with the Study Plan ; means the Feasibility Study Updates, the Feasibilit y Study Reports and any and all other data generated during the conduct of the Feasibility Study ; THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURIT IES AND EXCHANGE COMMISSION ( THE ) PURSUANT TO RULE 24B- 2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDEN TIAL TREATMENT TO SELECTED PORTIONS . ACCORDINGLY, THE CONFIDENTIAL PO RTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPA RATELY WITH THE COMMISSION . OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH